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ABSTRACT
The trimeric transcription factor NF-Y binds to the CCAAT box, an element 
enriched in promoters of genes overexpressed in tumors. Previous studies on the 
NF-Y regulome identified the general term metabolism as significantly enriched. We 
dissect here in detail the targeting of metabolic genes by integrating analysis of 
NF-Y genomic binding and profilings after inactivation of NF-Y subunits in different 
cell types. NF-Y controls de novo biosynthetic pathways of lipids, teaming up with 
the master SREBPs regulators. It activates glycolytic genes, but, surprisingly, is 
neutral or represses mitochondrial respiratory genes. NF-Y targets the SOCG (Serine, 
One Carbon, Glycine) and Glutamine pathways, as well as genes involved in the 
biosynthesis of polyamines and purines. Specific cancer-driving nodes are generally 
under NF-Y control. Altogether, these data delineate a coherent strategy to promote 
expression of metabolic genes fuelling anaerobic energy production and other anabolic 
pathways commonly altered in cancer cells.
INTRODUCTION
The CCAAT box is an important element present 
in promoters and enhancers of eukaryotic genes. It is 
bound by the evolutionarily conserved NF-Y (also named 
CBF), a trimer formed by NF-YA, NF-YB and NF-YC. 
NF-YB and NF-YC have histone-like structures, which, 
upon hetero-dimerization, present a complex surface for 
NF-YA association, in turn providing sequence-specific 
CCAAT recognition [1]. The use of genome-wide assays 
has generalized the concept previously derived by in 
vitro experiments that NF-Y is the primary CCAAT 
binding protein [2]. Yeast S. cerevisiae produces energy 
and ethanol through glycolysis and fermentation when 
grown in medium containing glucose; when challenged 
with non-fermentable carbon sources, yeast cells switch 
to oxygen-fueled metabolism, by activation of nuclear 
genes of the mitochondrial respiratory complexes. All 
these genes contain a CCAAT sequence in their regulatory 
UAS (Upstream Activating Sequences) sequences and are 
dependent upon the NF-Y yeast homologue HAP2/3/4/5 
[3].
In mammals, the NF-Y regulome is apparently 
more complex, but it is becoming intelligible, thanks 
to converging sets of data: (i) the precise biochemical 
characterization of the target sequence led to the definition 
of a DNA-binding matrix with high information content, 
characterized in hundreds mammalian promoters, 
highlighting a strong positional bias [4]; (ii) Genome-
wide experiments confirmed and further extended these 
observations to enhancers and other genomic regions 
[5-11]; (iii) Profiling analysis of genes whose expression 
is affected by functional inactivation of one of the 
subunits [11-13] found that in addition to a positive role 
on transcriptional units, NF-Y is also part of repressive 
mechanisms of transcription. 
A common theme in the analysis of the NF-Y 
regulome in mammalian cells is the presence of the term 
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metabolism at the top of Gene Ontology categorizations; 
functional dissection of individual promoters of metabolic 
genes indeed indicated the importance of NF-Y for high 
level of expression. There has been a renewed interest in 
the transcriptional control of such genes, since specific 
metabolic pathways are found altered in cancer cells; a 
vast array of biochemical, genetic and pharmacological 
data highlight the importance of the expression levels of 
single genes for “metabolic reprogramming”, an hallmark 
of the development and progression of tumors [14-16]. 
This is well exemplified by the recent computational 
evaluation of expression levels of genes of the SOCG 
-Serine One Carbon Glycine- pathway across cancer 
samples, indicating that collective overexpression of 
genes is predictive of the increased flux of metabolites 
observed in tumors [17]. Interestingly, analysis of large 
sets of expression profilings comparing tumors and 
normal tissues indicate that the NF-Y matrix is enriched 
in promoters of genes overexpressed in cancer cells [18]; 
however, it was not determined whether these genes 
belong to specific pathways. Finally, compelling genetic 
experiments have recently established that NF-YC, with 
TAF12 and RAD54L, is a driver oncogene of choroid 
plexus carcinomas [19].
For these reasons, we decided to take a closer look 
at the metabolic pathways influenced by the transcriptional 
activity of NF-Y. We analyzed available genomic data and 
performed additional gene expression experiments after 
inactivation of NF-Y subunits, to rationalize its role in the 
regulation of metabolic genes. The results point to specific 
pathways, and within them specific nodes, which are under 
tight NF-Y control.
RESULTS AND DISCUSSION
Experimental strategy
Top rank GO terms of NF-Y-regulated genes 
include metabolic pathways [11-13]. For this reason, we 
focused specifically on metabolic genes with the following 
strategy.
(i) We analyzed the results of Affymetrix gene 
expression profilings of Hela-S3 cells inactivated of NF-
YA by shRNA interference [11] and performed additional 
profilings in epithelial HCT116 and H322 cells under 
identical conditions of NF-YA inactivation. Fig. S1 shows 
the levels of NF-YA, as assessed by Western blot analysis; 
the complete list of genes up- and down-regulated in 
HCT116 and H322, considering a threshold of 1.3 fold 
difference, is in Fig. S2. Moreover, we analyzed the 
recently reported profilings data of mouse embryonic stem 
(mES) cells functionally inactivated of individual and of 
all three subunits of NF-Y [12].
(ii) To validate profilings, we analyzed the 
expression of selected genes of the affected pathways 
by qRT-PCR after inactivation of the NF-YB subunit in 
Hela-S3 cells with two different shRNAs.
(iii) To match function with location, we analyzed 
ChIP-Seq data of NF-YA and NF-YB in Hela-S3, 
GM12878 and K562 derived from ENCODE [9, 11], as 
well as the individual binding of the three subunits in 
mouse ES cells [12]. Specifically, we verified binding to 
the bona fide CCAAT matrix in the prototypical promoter 
position, between -60 and -100 from the TSS [4], as well 
as in distal locations classified as enhancers by virtue of 
the presence of appropriate epigenetic marks (H3K27ac, 
H3K4me1). 
The lack of NF-Y functional dependence in the 
presence of promoter binding might be due to an effective 
CCAAT-independence of the gene -and activity of 
compensatory TFs- or to the long half-life of the specific 
mRNA—the latter is a particularly relevant point, as 
we consider here housekeeping genes involved in basic 
metabolic functions, whose mRNAs tend to be relatively 
stable.
Overall density of NF-Y regulated genes in 
metabolic pathways
The profilings and ChIP-Seq data of Hela-S3 cells 
were first analyzed within the KEGG global metabolic 
chart. Genes whose expression is decreased after NF-YA 
inactivation are in red and those increased are in green 
(Fig. 1A); genes with core promoters bound by NF-
YA are in blue (Fig. 1B). The charts of gene expression 
profilings of human H322 and HCT116 cells after NF-YA, 
and of mouse ES cells after NF-YA, NF-YB and NF-YC 
inactivation, are shown in Figs. S3 and S4. Genes bound 
by NF-YB in Hela-S3, showing marginal differences with 
NF-YA, are in Fig. S5. Similarly, NF-YA and NF-YB 
binding in K562 and GM12878, as well as NF-YA, NF-
YB and NF-YC in mES cells are shown in Figs. S6-8. A 
bird’s eye view of the results collectively indicates high 
densities in areas of lipids, carbohydrates and nucleotides 
metabolisms. Other locations -glycan, vitamins, terpenoids 
and xenobiotics- are mostly depleted, with only selected 
genes positive. Aminoacids pathways show density in 
specific areas. We calculated the statistical significance of 
the regulated pathways in profilings of Hela-S3 and mES 
cells using KOBAS 2.0 [20], a software providing a better 
definition for the different metabolic sub-pathways. This 
led to the identification of globally enriched terms (Fig. 
S9). As previously reported [11], the Hela-S3 pathways 
at the top of the list are related to cell-cycle and mitosis, 
but specific metabolic terms are enriched and they are 
indeed predominant in mES cells. Focusing specifically 
on metabolic terms (Table 1), we note that anabolic genes 
are less expressed after NF-Y removal, whereas catabolic 
ones tend to be increased; among the formers, aminoacids 
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Figure 1: NF-Y targets in metabolic pathways. Global map of metabolic pathways targeted by NF-YA. A. Metabolic genes 
upregulated (in green) and downregulated (in red) after silencing of NF-YA in HeLa cells [11]. B. Metabolic genes with core promoters 
bound by NF-YA are indicated in blue according to ENCODE ChIP-Seq data. The maps are constructed with the KEGG Mapper v 2.5 tool.
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-notably Ala, Asp, Glu; Ser, Gly; Gln- lipids and 
nucleic acids are enriched. As for carbohydrate, carbon 
metabolism -mostly glycolysis- is enriched. We hereafter 
further examine the role of NF-Y in such pathways.
Lipids metabolism
NF-Y activates genes of the two main branches 
of lipids metabolism, cholesterol and fatty acids (Fig. 
2A): inactivation leads to decreased expression of most 
cholesterol genes, with the exception of HMGCS2, 
GGPS1, IDI1/2, HSD17B7, SC5D (Fig. 2A). A similar 
situation is observed for the fatty acids branch. With the 
exception of HMGCS2, IDI2 and PMVK, all promoters 
are bound in vivo in most cell types, including those 
negatively regulated in mES cells. Rate limiting enzymes 
of cholesterol -HMGCS1, HMGCR, Squalene Synthase 
(SQLE), DHCR - and fatty acids pathways -Acetyl COA 
Carboxylase (ACACA), Fatty Acids Synthase (FASN), 
Steatoryl CoA Desaturase (SCD)- were previously 
reported to be under NF-Y positive control [21-36]. Acyl-
CoA lyase (ACLY) and Acetyl-CoA synthase of the short 
chains (ACSS2) are also controlled.
Sustained proliferation rates of cells require a 
high level of de novo biosynthesis of lipids, which are 
incorporated into newly formed cell membranes. Indeed, 
these pathways are crucial for cancer cells, and many 
genes are overexpressed [37]. What is particularly relevant 
is that the genes more sensitive to NF-Y-inactivation are 
also those implicated in cancer development. On the 
cholesterol side, the mevalonate genes are overexpressed 
in many cancers, including HMGCS1, indeed a cancer-
driving gene [38], and the target of statins, a promising 
“new” class of anti-cancer drugs [39]. In the fatty 
acids branch, NF-Y targets FASN, SCD1 and GPAM, 
frequently overexpressed in tumors; FASN is a driver of 
neoplastic transformation [40]. ACSS2 is essential for 
transformation of acetate to Acetyl-CoA, thereafter used 
for lipids synthesis, as well as for histone acetylations 
[41,42]; expression of ACSS2 is high in many types of 
tumors and KO mice are protected in mouse models of 
liver carcinogenesis. The parallel strong NF-Y positivity 
of the less studied ACSM3 and ACSL3 invites evaluation 
Table 1: Metabolic terms enriched in genes whose expression is changed upon inactivation of NF-YA in Hela-S3 cells 
(left panel) and in mouse ES cells (mESC) (right panel). 
Pathways and Gene Ontology analyses were performed with Kobas 2.0 and metabolic terms extracted from the list. 
The full list of terms enriched in differentially expressed genes is shown in Fig. S9.
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of their expression levels across cancer samples, and role 
in tumorigenesis. Finally, ACLY is at the crossroad of 
lipids and glucose metabolism, mediating the production 
of Acetyl-CoA by transformation of cytoplasmic citrate to 
oxaloacetate. ACLY deregulation is generally observed in 
cancer, often correlating with tumor stage and prognosis 
[43] and silencing blocks proliferation of cancer cells 
by different mechanisms, impairing lipid biosynthesis, 
glycolytic enzymes, citrate accumulation and histones 
acetylation.
SREBP-1 and SREBP-2 are the master TFs of 
cholesterol and fatty acids biosynthesis [44]; the SREBP-1 
gene itself is controlled by NF-Y [45,46]. Genome-wide 
experiments reported a significant overlap between NF-YA 
and SREBP-1 sites [7], and enrichment of NF-Y sites in 
SREBP-1 peaks in mouse liver cells [47]. ChIP-Seq data 
of SREBP-1/2 in HepG2 and GM12878 were recently 
reported by the ENCODE consortium: inspection of 
binding to lipidogenic genes indicates a perfect correlation 
with NF-Y in cholesterol genes, and near perfect in fatty 
acids genes (SREBP1/2 positive promoters are marked in 
grey in Fig. 2A). We thus decided to analyze the global 
genomic overlap of NF-Y and SREBP-1/2: to do so, we 
used the PScan-ChIP software [48], which allows the 
identification of Transcription Factor Binding Site (TFBS) 
present in the JASPAR or TRANSFAC databases, as 
enriched in close proximity -<75 bps- of genomic peaks 
of a given TF. The statistical enrichment of positively 
correlating TFBSs is measured as “global” or “local“, 
depending on the robustness of the overlap (Fig. S10). 
The results of such analysis for SREBP-1 and SREBP-2 
are shown in Fig. 2B: the NF-Y consensus present in 
JASPAR -termed NFYA or NFYB- is significantly 
enriched in SREBP-1 and SREBP-2 peaks in HepG2 cells 
treated with pravastatin, but not in untreated GM12878 
(Fig. S10); similarly, SREBP-1 peaks are enriched in 
CCAAT boxes in HepG2 cells treated with insulin. For 
SREBPs in pravastatin treated HepG2, the program signals 
“global” enrichments -p values of 10-20- indicating that the 
CCAAT box is a “primary” binding site. By comparison, 
the SREBF motif has similar p values, indicating that the 
majority of SREBP-1 genomic sites in HepG2 have both 
a canonical SRE and a CCAAT box. No other TFBS is 
significantly enriched. The data of SREBP-1 peaks of 
insulin-treated HepG2 are very similar, except that RFX 
motifs also emerge, with similar frequencies (Fig. 2B). 
To validate these results, we used the MEME tools for 
de novo motif discovery, to inspect SREBP-1/2 genomic 
peaks: we indeed retrieved logos identical to the NF-Y 
binding site -the ATTGG reverse of CCAAT- in addition 
to the expected SRE sequence, and, in insulin-treated 
HepG2, the RFX logo (Fig. 2B). Thus, two types of 
analysis indicate that NF-Y and SREBPs share a vast set 
of genomic locations, extending beyond lipidogenic genes, 
at least in liver cells. Intriguingly, this is not observed 
in untreated GM12878 B cells, possibly suggesting 
treatment- or cell-type specific regulation.
Mechanistically, NF-Y and SREBPs are believed to 
serve different functions in transcriptional activation: the 
former as a “pioneer” TF, which binds to promoters and 
predispose a positive chromatin environment [11, 12, 49, 
50]; SREBPs as “activator” TFs promoting transcriptional 
elongation. In fact, nuclear translocation and DNA-
binding of SREBPs are visible under specific conditions: 
typically, this requires relocation from the ER into the 
nucleus, following addition of PTMs and proteolysis, 
according to specific stimuli [44, 47].
Respiratory genes, glycolysis and the TCA cycle 
The NF-Y homologue HAP2/3/5 is the master 
transcriptional activator of all genes of the respiratory 
chain in yeast, following the shift from fermentable 
(glucose) to non-fermentable (lactate) carbon sources [3]. 
The promoters of two human respiratory chain genes -ATP 
Synthase β/ATP5B and CYC1- were originally shown to 
rely on CCAAT boxes [51-54], and it could be inferred 
that NF-Y globally controls mammalian respiratory 
genes as well. The mitochondrial electron transport chain 
is composed of five complexes (I-V), each containing 
multiple subunits encoded by nuclear and mitochondrial 
genes. Surprisingly, we notice differential densities, 
both in genomic binding and transcriptional activation, 
in the areas of oxygen-fueled (low) and carbohydrate 
(high) metabolisms (Fig. 1); this is matched by KOBAS 
analysis, with terms such as aerobic respiration and 
oxidative phosphorylation being up-regulated upon 
NF-YA inactivation, hence normally repressed (Table 
1). Further analysis of the genes of the 5 respiratory 
complexes indicates the following: CYC1 (complex III) 
is -modestly- down-regulated in NF-Y-inactivated cells, 
but not bound by NF-Y; ATP5B (complex V) is bound 
and regulated; in general, however, only a handful genes 
-NDUFA2, NDUFS8, ATP5E, ATP5G1 and SDHB- are 
directly activated in cancer cells, eight genes in mES 
cells (Fig. 3A). A larger set of genes is repressed by NF-
Y, either through direct binding, or indirectly. We verified 
the expression analysis by inactivation of NF-YB through 
shRNA interference of Hela cells: of seven representative 
genes analyzed by qRT-PCR, either bound or not by NF-Y 
in vivo, four showed negligible changes, ATP6AP was 
modestly increased and CYC1 was modestly decreased, in 
accordance with the profilings data (Fig. 3B). Experiments 
using a second shRNA directed against NF-YB yielded 
similar results (Fig. S11). In summary, NF-Y activation of 
respiratory genes is globally an exception, and expression 
of most genes are either not controlled, or repressed.
On the other hand, glycolytic genes are densely 
populated of NF-Y-activated units (Figs. 1 and 4A). The 
sensitivity of such genes to NF-Y inactivation is very high 
in mES cells; PFKFB2 and SLC16A7 are the only genes 
showing up-regulation. Critical genes such as PFKFB, 
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Figure 2: NF-Y activates genes of lipid metabolism. A. Genes involved in cholesterol and fatty acids metabolisms are shown. 
The heatmap represents the log2 fold change of relative expression derived from profiling analysis (See colour scale) in the indicated cell 
lines after inactivation of NF-Y subunits: H322 (This manuscript, Fig S2), HCT116 (This manuscript, Fig. S2), HeLaS3 [11] and mESC 
[12]. The presence of NF-Y binding in ENCODE datasets is indicated with P (core promoter binding), E (external enhancer), Ei (enhancer 
in gene body) or R (repetitive sequence within 5 kb from the TSS). In vivo binding of SREB-1/2 according to ChIP-Seq experiments is 
indicated by a grey background. B. Analyses of over-represented motifs in SREBPs peaks in HepG2 ChIP-Seq data analyzed by ENCODE. 
The matrices were derived with Pscan-ChIP (Left panel) and MEME (Right panel), and the relative p-values are shown.
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PGK, GAPDH, PKM, LDH are bound and heavily rely on 
NF-Y activity. Note that Aldolase B, one of the first NF-Y 
promoters dissected [55, 56], is negative, possibly because 
it is mostly expressed in liver cells, not assayed here. 
Regulation is similar in cancer cells, with differences in 
SLC2A3, SLC16A7, PFKFB2/3 (in HCT116 and H322), 
PKM and HKII. Note that HKII and PKM promoters were 
shown to be NF-Y-dependent [57-59]. We verified the 
expression of some of these genes in NF-YB-inactivated 
Hela-S3 cells by qRT-PCR: most are decreased, with the 
exception of HKI, HKII and PKM (Fig. 4B and Fig. S11 
). We also checked the protein levels of several glycolytic 
enzymes, and found HKI, HKII, GAPDH and LDHA to be 
decreased, whereas PFKP was unchanged (Fig. 4C). These 
data are in agreement with the mRNA analysis, with two 
exceptions: HKII, whose protein is decreased and mRNA 
Figure 3: NF-Y and expression of respiratory genes. A. Genes of oxidative phosphorylation chain complexes are shown with the 
relative expression levels after inactivation of NF-Y in different cell lines, and the relative presence of NF-Y binding in P (promoter), E 
(external enhancer), Ei (enhancer in gene body) or R (repetitive sequence within 5 kb from TSS). B. qRT-PCR evaluation of expression 
levels of respiratory genes after inactivation of NF-YB in Hela cells. The average -/+ SD of three biological replicates is represented. 
(*p<0.05).
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Figure 4: Glycolytic enzymes are regulated by NF-Y. A. Genes encoding for glycolytic enzymes are shown with their expression 
levels after inactivation of NF-Y in different cell lines, and the presence of NF-Y binding is indicated as in Fig. 3. B. qRT-PCR evaluation 
of expression levels of selected genes after inactivation of NF-YB in Hela cells. The average -/+ SD of three biological replicates is 
represented. (*p<0.05). C. Western blot analysis of protein levels of NF-Y targets in Hela cells inactivated of NF-YA (Left panel), or NF-
YB (Right panel).
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is increased after NF-YA inactivation, and PKM, showing 
no change at the protein level. The differential effects 
could be due to the long half-life of the proteins, which 
would require assessment at longer times after NF-Y 
removal, or to the previously reported differences in sets 
of genes regulated by NF-YA and NF-YB inactivation 
[13]. 
Downstream of pyruvate, Acetyl-CoA enters the 
TCA cycle, which is functionally linked to mitochondrial 
oxidative phosphorylation: at the level of binding, the 
density of NF-Y sites in promoters is high, but the 
regulation is apparently complex and, intriguingly, 
somewhat dissimilar in cancer and mES cells (Fig. S12A). 
The Pyruvate Dehydrogenase -PDH- complex, leading 
to Acetyl-CoA production by oxidation of pyruvate, 
illustrates such complexity: PDHA1 is affected, but not 
Figure 5: Activation of SOCG genes by NF-Y. A. Genes of the SOCG (Serine, One Carbon, Glycine) pathway are shown with the 
expression levels after inactivation of NF-Y, and the presence of NF-Y binding as in Fig. 3. B. qRT-PCR evaluation of expression levels of 
PHGDH, PSAT1, PSPH, SHMT1 after inactivation of NF-YB in Hela cells. The average -/+ SD of three biological replicates is represented 
(*p<0.05).
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the DLD and DLAT subunits, which are, if anything, 
repressed by NF-Y; at the same time, the regulatory 
PD Kinase -PDK1/4- which inhibits the activity of the 
PDH complex, is robustly activated by NF-Y, as shown 
before [60]. Parallel pathways feed into oxalacetate 
from: (i) Phosphoenol-pyruvate via PCK (PEPCK), 
positively controlled by NF-Y, notably PCK2; (ii) 
Pyruvate Carboxylase (PC), which is bound -promoter 
and enhancer- and negatively regulated (Fig. S12A). The 
control of PC by NF-Y is also complex [61], including 
positive effects upon removal of single repressive CCAAT 
boxes [62]. Note the PC route is crucial for anaplerosis, 
that is, replenishment of the pools of the TCA cycle 
intermediates [63]. Production of citrate from Acetyl-CoA 
and oxaloacetate, and further to isocitrate, is mediated 
by Citrate synthase and Aconitase, whose promoters are 
bound in vivo, but modestly affected. Thereafter, enzymes 
are not uniformly regulated: Succinate Dehydrogenases 
(SDH) and Malate Dehydrogenase (MDH) are repressed 
by NF-Y in cancer cells (Fig. S12A). For IDH1/2, 
OGDH and FH, there is less significant regulation in 
the different cancer cell types analyzed, and a positive, 
indirect, effect on IDH2 in mES cells. We assayed some 
of the TCA genes by qRT-PCR after NF-YB inactivation 
in Hela cells: consistent with the profilings, PDHB, 
PDK1, ACLY but not PDHA1, are decreased, whereas 
OGDH, IDH2 and DLD are unchanged (Fig. S12B). In 
the second set of experiments using shNF-YB-2, the data 
are similar, except that OGDH is decreased, and PDHB 
is not, as in the profilings, (Fig. S11). The protein levels 
of PDHA were evaluated in Western Blots and found to 
be unchanged (Fig. S12C). Note that NF-Y appears to 
promote expression of enzymes converting α-ketoglutarate 
and malate out of the TCA cycle (See below). In summary, 
NF-Y does bind to most promoters of TCA cycle genes, 
but its role is less relevant, and possibly cell-type specific; 
in general, it does not uniformly favor the progression of 
Acetyl-CoA derived from glucose, lipids and aminoacids 
catabolism through the oxidative production of energy, 
particularly in cancer cells. Again, this is in striking 
contrast to the results obtained in yeast, where the CIT1, 
IDH, FH and MH genes are robustly activated by the 
HAP2/3/4/5 complex during activation of the respiratory 
response [64].
A major and unexpected finding of our analysis is 
that the control of energy metabolism by NF-Y changed 
during evolution, from promoting mitochondrial energy 
production, in fungi, to activating genes of anaerobic 
pathways, in mammals. The preference for anaerobic 
energy production by glycolysis in the presence of oxygen 
is a hallmark of cancer cells, a phenomenon known as 
the Warburg effect [65]. This requires a high activity 
of glycolytic enzymes; accordingly, the overall levels 
of many of them are elevated in many types of tumors, 
with respect to normal cells, mainly because of increased 
mRNA expression [66]. 
In general, NF-Y appears to have a coherent strategy 
of promoting glucose, but not oxygen utilization. Among 
glycolytic enzymes, GAPDH produces Glyceraldeyde-
3P, which enters the biosynthetic pathway of Serine 
biosynthesis (See below). PKM promotes the final, 
rate-limiting step of glycolysis to generate pyruvate 
and ATP and is important in cancer cells [67]. Lactate 
Dehydrogenases are key to drive regeneration of NAD+ 
and continuous ATP production from glycolysis. Lactate 
Dehydrogenase is produced by two genes -LDHA and 
LDHB- whose relative expression varies depending upon 
the cellular status: in cancer cells, it is shifted toward 
LDHA, generating the LDH5 enzyme, most efficient in 
driving the Pyruvate-to-Lactate conversion required to 
keep the glycolytic flux flowing [68]. It is thus noteworthy 
that NF-Y is more important for LDHA expression in 
cancer cells, and for LDHB in mESCs. At the end of 
glycolysis, NF-Y does not appear to promote a flux of 
Acetyl-CoA entering the TCA cycle: this is exemplified 
by the modest impact on PDH, on the associated subunits, 
and activation of its repressor PDK. At the same time, 
NF-Y promotes exit of α-ketoglutarate and malate from 
the TCA cycle to enter alternate pathways, in cancer cells 
at least (See below).
Long time considered as housekeeping genes 
subject to modest levels of regulation, the promoters of 
these genes recently regained interest, but information 
about the DNA elements and TFs acting on many of them 
remains scarcely abundant. HIF-1α, MYC, STAT3 and 
p53 are TFs associated with the regulation of glycolytic 
enzymes [69-74]. The formers are generally activators, 
while p53 is inhibitory, at least in the wt configuration. 
HIF-1α is activated by anaerobic stress and constitutively 
active in many cancer cells, targeting essentially all 
glycolytic genes; MYC was shown to interact with NF-Y 
directly [75] and the peaks of MYC and NF-Y overlap 
significantly in ENCODE data [11]. Interestingly, p53 was 
shown to promote gluconeogenesis [76], while oncogenic 
Gain-of-Function mutations of p53, reported to impact 
on expression of NF-Y genes [77, 78], mediate metabolic 
reprogramming and increased glycolysis [79]: it will 
be interesting to evaluate the effects of mutp53 on the 
metabolic genes targeted by NF-Y identified here. 
The SOCG and Glutamine pathways
We noticed high densities of NF-Y targets in 
specific pathways of Serine/Glycine, Glutamine and 
Methionine, all enriched in KOBAS analysis (Table 1). 
The SOCG pathway is central for de novo production 
of Serine and Glycine, and for additional metabolisms 
-folates, nucleotides- crucially required for growing 
cells [80]. NF-Y binding is present on all promoters of 
the pathway in at least one cell type with the exception 
of the SLC19A1 transporter, MTHFD2L and AMT 
(Fig. 5A). Serine synthesis stems from a branch of 
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glycolysis, through Glyceraldeyde 3P being sequentially 
metabolized by three enzymes: PHGDH, PSAT and 
PSHP; the promoters are all bound, and the mRNAs 
decreased upon NF-YA removal. For the PHGDH 
promoter, genetic evidence of the importance of the 
CCAAT box was reported [81]. Conversion to Glycine is 
then obtained through the activity of SHMT, present in 
two isoforms, one located in the cytoplasm -SHMT1- the 
other -SHMT2- in mitochondria: NF-YA regulates the 
former, but apparently not the latter. qRT-PCR analysis 
of Hela-S3 cells inactivated with the two shRNAs against 
NF-YB confirmed the control of PHGDH, PSAT1, PSPH, 
whereas SHMT1 was, if anything, positively affected 
(Fig. 5B and Fig. S11). Interestingly, NF-Y also impacts 
on the mitochondrial branch, by activation of two key 
enzymes, MTHFDL1 and MTHFD2. Control of MTHFR 
and DHFR signals a further role on folates metabolism, 
which is linked to Methionine synthesis and nucleotides 
production (See below). In summary, the data indicate that 
NF-Y plays a crucial role in the activation of SOCG genes.
Glutamine is another pathway dense with NF-Y 
targets, at the level of promoter recognition and function 
(Fig. 5A). Binding of NF-Y is absent only in SLC3A2, 
CAD, SLC38A5 and SLC38A3; the latter gene, GLUD1 
and GPT are unchanged in expression after NF-YA-
inactivation in cancer cells. Most genes are activated by 
NF-Y through direct promoter binding [82]. Specifically, 
GLS and GLS2 are differentially regulated in Hela-S3 and 
mES cells: the former is bound and activated in Hela-S3 
(but repressed in H322), but not regulated in mES cells. 
The reciprocal is true for GLS2. These enzymes are 
crucial for the conversion of Glutamine to Glutamate, 
which can then be transformed to α-ketoglutarate by 
GLUD1, not regulated by NF-Y in cancer cells and 
modestly repressed in mES cells. This branch is a second 
leg of anaplerotic mechanisms filling the TCA cycle with 
metabolites from the Glutamine pathway: the positivity 
of GOT1/2, but not GLUD1, is yet another indication that 
NF-Y is not favoring anaplerosis per se. GOT1/2, in fact, 
convert Aspartate from Glutamine into oxaloacetate, then 
converted into malate [83]: thereafter, the Malic enzymes 
ME1 ME2, both regulated by NF-Y (Fig. 5A), mediate 
Figure 6: Activation of genes of the polyamine metabolism by NF-Y. Genes of the polyamine pathway are shown with the 
expression levels after inactivation of NF-Y, and the presence of in vivo NF-Y binding as in Figs. 3-5.
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pyruvate production and exit from TCA. In summary, 
NF-Y appears to promote a shift of Glutamine catabolism 
from the TCA cycle into alternative biosynthetic pathways, 
matching the modest role exerted on PDH (Fig. S12A). 
The negative regulation of SDH (Fig. 3A and S12A) 
and the activation of genes deviating metabolites from 
the TCA cycle are a further indication that NF-Y is not 
promoting oxygen-mediated production of energy.
The Glutamine and SOCG pathways are altered 
in cancer cells. As to the former, tumors usually become 
addicted to high levels of Glutamine. The key GLS2 is 
activated by p53 [84, 85], and regulation is shared by 
p63 and p73, with a different outcome depending from 
the isoforms [86, 87]. Genes of the SOCG pathways 
are overexpressed in cancer [88], the global alteration 
directly impinges on an altered flux of metabolites 
[17]. PHGDH and SHMT2 are predictive of survival 
outcomes in breast cancer, PSPH of hepatocellular 
carcinomas [89,90]. SHMT2 is a cancer driver gene [91, 
92]; PHGDH overexpression, resulting from genomic 
amplification, is essential for growth of certain human 
breast cancers [93] and melanomas [94]; PSAT1 is 
overexpressed in colon cancer [95]. In general, there 
are very few data on the mechanisms of transcriptional 
regulation of SOCG pathway genes: p53 is a repressor 
of PHGDH [96], whereas cMYC overexpression leads to 
increased biosynthesis of serine [90]. The identification of 
NF-Y/CCAAT as a pivotal element should facilitate the 
identification of neighboring elements and TFs involved 
in regulation of these units.
Polyamine and purine metabolism
The biosynthetic pathways of purines and 
polyamines have high density of NF-Y-controlled genes 
(Fig. 1 and Table 1). In the polyamine pathway, which is 
extremely important for cancer cells (97), there are two 
rate-limiting steps, mediated by ODC1, from the Urea 
cycle, and AMD1, from the Methionine salvage pathway. 
AMD1 is directly controlled by NF-Y in cancer and mES 
cells, but NF-Y inactivation also leads to an indirect 
decrease of ODC1 (Fig. 6A). Additional regulated genes 
are ADI1, AGMAT, GOT1, SMOX, SMS and SRM. 
ADI1, AMD1, GOT1 and SRM were tested in Hela-S3 
cellsinactivated of NF-YB: GOT 1 was unaffected, ADI1 
was substantially decreased, AMD1 and SRM decreased 
with one of the shRNAs used (Fig. 6B and Figure S11). 
AMD1 and ODC1 are deregulated in a number of 
cancers, notably prostate adenocarcinomas and MYCN-
amplified neuroblastomas: in the latter system, ODC1 is 
required for tumor formation and overexpression predicts 
patient survival [98]. ODC1 pharmacological inhibition 
leads to normalization of several pathways -NMYC 
levels, LIN28/Let-7 expression and glycolysis- altered in 
neuroblastomas, and it is currently tested in clinical trials 
[99]. Interestingly, ODC1 and AMD1 are independently 
involved in mESC self-renewal, in assays of LIF-deprived 
cells, and can increase reprogramming of differentiated 
fibroblasts by OCT4, SOX2 and KLF4 [100]. NF-Y is also 
involved in mESC self-renewal [12, 101, 102]: a positive 
role on expression of the three TFs was reported, as an 
important part of the cohort of NF-Y targets involved in 
stem cells maintenance.
Many genes of the purine pathway are under 
NF-Y control (Fig. S13); two targets are bona fide tumor 
suppressors: MTAP, frequently deleted in many types of 
cancers along with the neighboring CDKN2A [103], and 
Adenylate Kinase 2 AK2 [104]. MTAP shows differential 
AK2 shows regulation by NF-Y, repressed in cancer cells 
and in mES cells. As for the synthesis of dNTPs required 
for the DNA biosynthetic pathways (DNA replication and 
repair), the key step is the reduction from ribonucleotides 
to desossiribonucleotides, performed by the rate-
limiting enzyme Ribonucleotide Reductase (RnR), an 
heterotetramer composed of two large (RRM1) and two 
small (RRM2) subunits. While RRM1 is abundant and 
constant throughout the cell-cycle, the limiting RRM2 
is transcribed only in S-phase [105]. RRM1 is regulated 
by NF-Y in Hela-S3 cells, but the dependence is higher 
for RRM2 (Fig. S13), whose promoter contains three 
functionally crucial CCAAT boxes [106], conserved 
and important also in Zebrafish [107]. Recently, RRM2 
has attracted considerable therapeutic interest, because 
its targeting leads cancer cells to senesce [108, 109]. It 
is important to note that cells inactivated of NF-YA are 
crippled in S-phase progression, develop signs of DNA-
damage, with subsequent triggering of an apoptotic 
response [12, 13]: it is possible that a decrease in the 
dNTPs pools, due to a decrease in the conversion from 
Figure 7: Schematic representation of metabolic pathways regulated by NF-Y.
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NTPs as a consequence of the RRM2 drop, might be at 
least partially responsible for this behavior. 
CONCLUSIONS AND PERSPECTIVES
The detailed analysis of metabolic genes under 
the control of NF-Y described here and summarized in 
Fig. 7 opens several future avenues of investigations: 
(i) A thorough phylogenetic analysis of the conservation 
of CCAAT boxes in metabolic genes targeted by NF-Y 
should be performed; specifically, genes involved in 
energy production should be examined, to identify 
when the switch from aerobic -in yeast- to anaerobic 
-in mammals- energy production has occurred during 
evolution: (ii) Further studies should be undertaken on 
the many NF-Y metabolic targets whose role in cancer 
development is unknown. Systematic investigation of 
their expression levels in large cohorts of gene expression 
data of cancer cells could point at additional regulatory 
nodes to be further examined experimentally by genetic 
and biochemical means: (iii) A few TFs known to impact 
on transcription of metabolic genes emerged, and some 
have been associated to NF-Y activity; in this regard, the 
SREBP analysis performed here is illustrative of what can 
be done, given the availability of large datasets of TFs 
genomic sites; the identification of major NF-Y partners 
in the regulation of metabolic genes will shed light on the 
arrangement of promoter sites and reciprocal interplay. 
Such catalogue will help our understanding of regulatory 
circuits of cancer cells.
MATERIALS AND METHODS
Lentiviral knockdown and gene expression arrays 
Scrambled control (shSC), NF-YA (shNF-YA) and 
two NF-YB (shNF-YB-1 -gctatgtctactttaggcttt-; shNF-
YB-2 -ccaaagaatgtgttcaagaatc-) shRNAs were cloned 
into pLKO.1 vector (Sigma Aldrich), and viral production 
and transduction were carried out as previously described 
[13]. H322 and HCT116 cells were transduced with 
shSC or shNF-YA viral supernatants, in triplicate, and 
cells collected after 72 hrs of incubation. Hela-S3 cells 
were infected with shSC or shNF-YB or shNF-YA and 
collected at 72 hrs after infection. In the experiments 
shown in Figure S11, transient DNA transfections with 
shSC and shNF-YB-2 were performed in triplicate with 
Lipofectamine 2000 (Invitrogen 11668027). Cells were 
collected after 72 hours. Knockdown efficiency was 
assayed by PCR on cDNAs and by Western Blots on 
whole cell protein extracts using anti-NF-YA, anti NF-
YB and anti-Actin antibodies. Total RNA was prepared 
by Trizol extraction and retrotrascribed with Iscript cDNA 
Synthesis kit (BIORAD 170-8890). For arrays, RNA was 
prepared according to Affymetrix standard protocol and 
hybridized to Hu-Gene 2.0 expression arrays.
Gene expression analyses 
For HeLa-S3 cells, raw data were retrieved from 
GSE40215 [11]; for mouse embryonic stem cells, raw data 
were retrieved from GSE56840 [12]. For gene expression 
analysis of HCT116 and H322 using the Affymetrix 
platform, biological triplicates of control and shNF-YA-
treated cells were independently processed: normalization 
(rma), quality controlled, probe set filtered, identification 
of differentially expressed probe sets and annotation of 
those probe sets to gene symbols were performed using 
Bioconductor packages (Affy and Limma). We defined 
upregulated and downregulated genes when the fold 
change is above 1.3 and FDR <0.05. Gene Ontologies 
and pathways analyses were performed using the KOBAS 
2.0 tool with default settings [20]. Raw data have been 
deposited in GEO Repository under the accession number 
GSE70543.
Immunoblots
For Western Blot analysis, NF-Y-inactivated and 
control cells were lysed in lysis buffer (50mM Tris–
HCl pH 8.0, 120mM NaCl, 1% Triton X100, 20%SDS, 
1mM EDTA, protease and phosphatase inhibitors). 
Equivalent amount of extracts were run on SDS-PAGE, 
transferred to nitrocellulose membrane (Whatman) and 
immunoblotted with the following antibodies: anti-Actin 
(sc-1616, Santa Cruz) anti-NF-YA (Mab1a), anti-NF-YB 
(Pab001, GeneSpin), anti-Glycolytic enzymes (Glycolysis 
2 kit, Cell Signaling 8337S), anti-Vinculin (SAB4200080, 
Sigma Aldrich).
qRT-PCR 
The Primer3 0.4.0. program was used for primers 
design using default parameters. See Fig. S14 for primer 
sequences. qPCR was performed with a Biorad myIQ 
instrument: values are normalized over an internal control 
ribosomal gene used as normalizator -RPS20- and are 
represented as fold-enrichment over control sample 
shSC. Data are presented as mean ± standard error of fold 
change of 3 biological replicates run in qPCR triplicates. 
Statistical significance are assessed with one sample t-test 
and indicated with asterisk when p<0.05.
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